Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim

Last Updated: December 10, 2019

DrugPatentWatch Database Preview

Litigation Details for Pfizer Inc. v. Apotex Inc. (N.D. Ill. 2008)

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Pfizer Inc. v. Apotex Inc. (N.D. Ill. 2008)

Docket   Start Trial Date Filed 2008-12-17
Court District Court, N.D. Illinois Date Terminated 2012-03-01
Cause 35:145 Patent Infringement Assigned To Edmond E-Min Chang
Jury Demand Defendant Referred To Honorable Martin C. Ashman
Patents 4,681,893; 4,895,841; 5,273,995; 5,686,104; 6,126,971
Attorneys Andrew M Alul; Dean A. Monco; Deanne M. Mazzochi; Jeffrey B. Bove; Paul J. Molino; William Andrew Rakoczy
Link to Docket External link to docket
Small Molecule Drugs cited in Pfizer Inc. v. Apotex Inc.
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for Pfizer Inc. v. Apotex Inc. (N.D. Ill. 2008)

Date Filed Document No. Description Snippet Link To Document
2009-11-12 114 III certification against U.S. Patent No. 4,895,841 (“the ‘841 patent”), which meant that Ranbaxy could…during the patent term of the ‘841 patent. Here, Apotex has agreed to wait out the full patent term of …the ‘995 patent and its reissue (RE667) on which Pfizer originally sued, but also three patents (the ‘104…‘104, ‘156, and ‘971 patents or “non-asserted patents”) which Pfizer has never asserted against Apotex…Mylan for infringement of the ‘156 patent as well as on two other patents not at issue here. Pfizer Inc. External link to document
2009-11-12 116 (“‘667 patent”).2 And Apotex Inc.’s paragraph III certification to U.S. Patent No. 4,681,893 is not …position that U.S. Patent No. 5,273,995 (“‘995 patent”), which, together with the ‘667 patent, make up the …collectively, “Pfizer”) have asserted U.S. Patent No. 5,969,156 (“‘156 patent”) against subsequent ANDA-filers…sued on that patent (and others), precisely because Pfizer has never asserted those patents against any…‘156, And ‘971 Patents Against Generic Competitors By Asserting The ‘156 Patent Against Mylan External link to document
2010-06-30 142 the ‘ United States Patent No. 5,273,995 (“ 995 patent” …issued U.S. Patent No. RE40,667 (“ 667 ). The ‘ patent” 667 patent is a reissue patent, which… of such patent * * *, reissue the patent for the invention disclosed in the original patent” …on Double Patenting Courts have interpreted the Patent Act to forbid a second patent from covering…well as the Patent Office Rules require surrender of the original patent before a reissue patent may be granted External link to document
2010-06-30 144 156 patent, the ‘ and U.S. Patent No. 4,681,893 (“ … the ‘ 995 patent was reissued in part as U.S. Patent No. 40,667 (“ 667 patent” …well as three other Pfizer patents: U.S. Patent Nos. 5,686,104 (“ 104 patent” … 893 patent and the ‘ 995 patent. The district court found both patents to be valid and… the ‘ United States Patent No. 5,273,995 (“ 995 patent External link to document
2010-07-09 148 March 24, 2010, the expiration date of U.S. Patent No. 4,681,893 plus pediatric exclusivity). (See D.I. 68…March 24, 2010, the expiration date of U.S. Patent No. 4,681,893 plus pediatric exclusivity), is relevant…defeating U.S. Patent No. 5,273,995 (“the ‘995 patent;” the patent from which the ‘667 patent reissued). …Pfizer on U.S. Patent Nos. 5,686,104 (“the ‘104 patent”), 5,969,156 (“the ‘156 patent”), and/or 6,126,971… constitutes patent misuse). Patent misuse is an equitable defense that renders a patent unenforceable External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:


Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.